Abstract 123P
Background
To study the relationship between prognostic nutritional index (PNI) and clinicopathological factors in gastroesophageal junction cancer patients with postoperative anastomotic leakage and the clinical significance of PNI in predicting the survival of patients with postoperative anastomotic leakage.
Methods
Clinicopathological and follow-up data of 115 gastroesophageal junction cancer patients with anastomotic leakage after radical surgery in the Department of Thoracic Surgery, the 4th Hospital of Hebei Medical University from January 1 2004 to December 31 2013 were retrospectively analyzed. PNI values were calculated [PNI = absolute lymphocyte count (109/L) x 5 + serum albumin (g/L)], and was grouped according to the PNI mean value. Relationships of PNI with patient gender, age, tumor stage, tumor differentiation, tumor location, lymph node metastasis were analyzed. For survival analysis, log-rank method was used for univariate analysis, and Cox method was used for multivariate analysis.
Results
The mean PNI of patients with anastomotic leakage was 48.51 (43.25∼56.25). The 5-year survival rate of patients with PNI ≤48.51 was 58.9%, and the 5-year survival rate for patients with PNI>48.51 was 59.3%. There was no significant difference between the two groups (χ2=0.127, P=0.722). Univariate and multivariate analysis showed that N stage is an independent risk factor for the prognosis of patients with PNI≤48.51. Postoperative adjuvant treatment is an independent risk factor for the survival of patients with PNI>48.51. P for interaction between PNI and treatment modality: P=0.037.
Conclusions
The independent prognostic factors of patients with esophagogastric junction adenocarcinoma combined with anastomotic leakage are N stage and adjuvant treatment for PNI≤48.51 and PNI>48.51 group, respectively. For patients with esophagogastric junction adenocarcinoma combined with anastomotic leakage, PNI is an important factor for guiding the selection of appropriate postoperative treatment.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The Fourth Hospital of Hebei Medical University.
Funding
Has not received any funding.
Disclosure
The author has declared no conflicts of interest.
Resources from the same session
194P - Nab-paclitaxel plus capecitabine as first-line treatment for patients with recurrence or metastatic biliary tract cancer
Presenter: Jun Zhou
Session: e-Poster Display Session
370P - Bespoke circulating tumour DNA assay for the detection of minimal residual disease in esophageal adenocarcinoma patients
Presenter: Emma Ococks
Session: e-Poster Display Session
390P - A real-world clinical study of camrelizumab in the treatment of esophageal cancer
Presenter: Guoping Sun
Session: e-Poster Display Session
203P - Characterization of renal cell carcinoma (RCC) with VHL mutation
Presenter: Yanrui Zhang
Session: e-Poster Display Session
204P - Prospective observational study on pazopanib in patients treated for advanced or metastatic renal cell carcinoma (RCC) in Asia, North Africa and Middle East countries: Final analysis of PARACHUTE study
Presenter: Ravindran Kanesvaran
Session: e-Poster Display Session
205P - A study on organ preservation in muscle invasive urinary bladder cancer patients with intensity modulated radiotherapy and concurrent single agent cisplatin in south Indian population
Presenter: Himani Manchala
Session: e-Poster Display Session
206P - Mutational signature in urothelial carcinoma with TP53 mutation
Presenter: Huan Liu
Session: e-Poster Display Session
207P - Concordance of genomic alterations by next-generation sequencing in tumour tissue versus circulating tumour DNA in urothelial carcinoma
Presenter: wang Wang
Session: e-Poster Display Session
208P - Prognostic factors and outcomes of non-seminomatous germ cell tumours of testis: Experience from a tertiary cancer centre in India
Presenter: Lekha Nair
Session: e-Poster Display Session
210P - Prognostic value of sarcopenia in metastatic renal cell carcinoma patients: A systematic review
Presenter: Angeline Tancherla
Session: e-Poster Display Session